CRISPR Therapeutics AG (CRSP) Convertible Debt (2015)

CRISPR Therapeutics AG's (CRSP) quarterly Convertible Debt came in at $38.3 million in Q4 2015.

CRISPR Therapeutics AG (CRSP) Convertible Debt (2015) Analysis & Trends

CRISPR Therapeutics AG has disclosed Convertible Debt across 1 years of filings, most recently posting $38.3 million for Q4 2015.

Convertible Debt for Q4 2015 came in at $38.3 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2015 was $38.3 million (changed N/A YoY), and the FY2015 annual result was $38.3 million, changed N/A from the prior year.
Convertible Debt came in at $38.3 million for Q4 2015 at CRISPR Therapeutics AG.
In the past five years, Convertible Debt ranged from a high of $38.3 million in Q4 2015 to a low of $38.3 million in Q4 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	CRISPR Therapeutics AG	5.21 Bn	2.76 Bn	-

Download Data

Date	Value
Dec 31, 2015	38.34 Mn